Publications by authors named "Justyna Mierzynska"
Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43-0·74]; p<0·0001). This study reports the results from the health-related quality-of-life (HRQOL) exploratory endpoint.
Methods: This double-blind, randomised, controlled, phase 3 trial was done at 123 academic centres and community hospitals across 23 countries.
Objectives: To provide reference values for the European Organisation for Treatment and Research of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) in advanced-stage Hodgkin lymphoma (HL) patients and 5-year HL survivors. The QLQ-C30 is the most widely used cancer-specific questionnaire to assess Health-Related Quality of Life (HRQoL).
Methods: The EORTC database was searched to identify HL RCTs in which patients' and survivors' HRQoL was assessed by the QLQ-C30.
Article Synopsis
- The study aimed to provide reference values (RVs) for health-related quality of life (HRQoL) in breast cancer patients, comparing early breast cancer (EBC) and metastatic breast cancer (MBC) using two different datasets.
- Analysis included data from both the European Organization for Research and Treatment of Cancer (EORTC) and Project Data Sphere (PDS), revealing that EBC patients generally reported better HRQoL compared to MBC patients, who faced more severe symptoms and lower functioning scores.
- The findings highlight that baseline HRQoL varies significantly with disease stage, performance status, and comorbidities, and the provided RVs will enhance clinical assessments and comparisons in future breast cancer research.
Article Synopsis
- A review from 2008 emphasized the importance of baseline patient-reported outcomes (PROs) as significant independent predictors of cancer patients' overall survival in clinical studies.
- In response to earlier studies' limitations, new recommendations were made to improve methodological rigor in prognostic factor research.
- Our updated systematic review of 44 studies from 2006 to 2018 showed enhanced standardization and rigor in methods, with 93% reporting at least one PRO domain as prognostic, particularly highlighting physical functioning and quality of life as key factors.